All Visus Therapeutics articles
-
News briefs
J&J takes part in a $36m round for the development of presbyopia correction eye drops
Visus Therapeutics , an American pharmaceutical company based in Seattle, announced yesterday the completion of a $36 million financing round to fund the company’s research on its Brimochol product, an eye drop drug designed to correct the effects of presbyopia with one daily application. The drug is currently in ...
